After speaking at last week’s Republican National Convention in Cleveland, New Mexico OD Lisa Shin says more optometrists should get involved on a national level to keep optometry’s agenda at the forefront.
The pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.
Device manufacturers presenting new implants and technologies to treat glaucoma. As the industry moves from 1.0 devices to 2.0 devices, this will be a transformative time in the way physicians treat patients.